RC
CTNM

RBF Capital’s Contineum Therapeutics CTNM Stock Holding History

RBF Capital’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$261K Hold
20,000
– – 0.01% 436
2025
Q4 		$229K Sell
20,000
-20,000
-50% -$228K 0.01% 503
2025
Q3 		$470K Hold
40,000
– – 0.02% 412
2025
Q2 		$159K Buy
+40,000
New +$174K 0.01% 548

Other funds holding CTNM

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RBF Capital's CTNM Position: Q1 2026 in Review

RBF Capital held its Contineum Therapeutics (CTNM) position steady in Q1 2026 at 20,000 shares worth $261K. The position accounts for 0.01% of the portfolio, ranked #436.

RBF Capital first reported a position in CTNM in Q2 2025 and has held it in 4 quarters since. The position peaked at $470K in Q3 2025. 90 funds tracked by Wall St. Rank hold CTNM as of Q1 2026.

  • RBF Capital held 20,000 shares of Contineum Therapeutics worth $261K as of Q1 2026.
  • RBF Capital left its Contineum Therapeutics share count unchanged in Q1 2026.
  • Contineum Therapeutics made up 0.01% of RBF Capital's portfolio in Q1 2026, its #436 holding.
  • RBF Capital first reported a position in Contineum Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • RBF Capital's Contineum Therapeutics position peaked at $470K in Q3 2025.
  • 90 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q1 2026.

Based on RBF Capital's 13F filing for Q1 2026, filed 15 May 2026.